|
US3024257A
(en)
|
1961-04-10 |
1962-03-06 |
Frosst & Co Charles E |
Stable preparations of alkali metal salts of estrone sulfate
|
|
FR2340735A1
(fr)
|
1976-02-11 |
1977-09-09 |
Roussel Uclaf |
Nouveaux derives de l'acide 3-quinoleine carboxylique, leur procede de preparation et leur application comme medicament
|
|
IE52670B1
(en)
|
1981-03-03 |
1988-01-20 |
Leo Ab |
Heterocyclic carboxamides,compositions containing such compounds,and processes for their preparation
|
|
DE3437232A1
(de)
|
1984-10-10 |
1986-04-17 |
Mack Chem Pharm |
Stabilisierte injektionsloesungen von piroxicam
|
|
US4782155A
(en)
|
1986-03-19 |
1988-11-01 |
Banyu Pharmaceutical Co., Ltd. |
Cephalosporin derivatives, processes for their preparation and antibacterial agents
|
|
US5139878A
(en)
|
1991-08-12 |
1992-08-18 |
Allied-Signal Inc. |
Multilayer film constructions
|
|
US5540934A
(en)
|
1994-06-22 |
1996-07-30 |
Touitou; Elka |
Compositions for applying active substances to or through the skin
|
|
US5912349A
(en)
|
1997-01-31 |
1999-06-15 |
Pharmacia & Upjohn Company |
Process for the preparation of roquinimex
|
|
US20030124187A1
(en)
|
1997-02-14 |
2003-07-03 |
Smithkline Beecham Laboratoires Pharmaceutiques, |
Pharmaceutical formulations comprising amoxycillin and clavulanate
|
|
US6696407B1
(en)
|
1997-03-21 |
2004-02-24 |
The Regents Of The University Of California |
Huntington's disease treatment comprising administering aldose reductase inhibitors to increase striatal CNTF
|
|
GB9726339D0
(en)
|
1997-12-13 |
1998-02-11 |
Zeneca Ltd |
Human-derived tissue-specific potassium channel
|
|
US6077851A
(en)
|
1998-04-27 |
2000-06-20 |
Active Biotech Ab |
Quinoline derivatives
|
|
SE9801474D0
(sv)
|
1998-04-27 |
1998-04-27 |
Active Biotech Ab |
Quinoline Derivatives
|
|
SE9802550D0
(sv)
|
1998-07-15 |
1998-07-15 |
Active Biotech Ab |
Quinoline derivatives
|
|
US6133285A
(en)
|
1998-07-15 |
2000-10-17 |
Active Biotech Ab |
Quinoline derivatives
|
|
US6121287A
(en)
|
1998-07-15 |
2000-09-19 |
Active Biotech Ab |
Quinoline derivatives
|
|
SE9802549D0
(sv)
|
1998-07-15 |
1998-07-15 |
Active Biotech Ab |
Quinoline derivatives
|
|
RS51019B
(sr)
|
1999-10-25 |
2010-10-31 |
Active Biotech Ab. |
Lekovi za lečenje malignih tumora
|
|
EP1365794A2
(en)
|
2000-07-21 |
2003-12-03 |
Lue, Tom |
Prevention and treatment of sexual arousal disorders
|
|
US6307050B1
(en)
|
2000-08-29 |
2001-10-23 |
R. T. Alamo Venture I Llc |
Method of synthesizing flosequinan from 4-fluoroanthranilic acid
|
|
US6802422B2
(en)
|
2000-12-12 |
2004-10-12 |
Multi-Comp, Inc. |
Sealed blister assembly
|
|
US6706733B2
(en)
|
2001-05-08 |
2004-03-16 |
Dainippon Ink And Chemicals, Inc. |
Quinolinone derivative formulation and its production method
|
|
US20030119826A1
(en)
|
2001-09-24 |
2003-06-26 |
Pharmacia Corporation |
Neuroprotective treatment methods using selective iNOS inhibitors
|
|
US7560557B2
(en)
|
2002-06-12 |
2009-07-14 |
Active Biotech Ag |
Process for the manufacture of quinoline derivatives
|
|
SE0201778D0
(sv)
|
2002-06-12 |
2002-06-12 |
Active Biotech Ab |
Process for the manufacture of quinoline derivatives
|
|
US6875869B2
(en)
|
2002-06-12 |
2005-04-05 |
Active Biotech Ab |
Process for the manufacture of quinoline derivatives
|
|
CA2490043A1
(en)
*
|
2002-06-25 |
2003-12-31 |
Merck Frosst Canada & Co. |
8-(biaryl) quinoline pde4 inhibitors
|
|
US7820145B2
(en)
|
2003-08-04 |
2010-10-26 |
Foamix Ltd. |
Oleaginous pharmaceutical and cosmetic foam
|
|
US20070292461A1
(en)
|
2003-08-04 |
2007-12-20 |
Foamix Ltd. |
Oleaginous pharmaceutical and cosmetic foam
|
|
US7790197B2
(en)
|
2003-06-09 |
2010-09-07 |
Warner-Lambert Company Llc |
Pharmaceutical compositions of atorvastatin
|
|
US20050271717A1
(en)
|
2003-06-12 |
2005-12-08 |
Alfred Berchielli |
Pharmaceutical compositions of atorvastatin
|
|
CA2528723A1
(en)
|
2003-06-25 |
2005-01-06 |
Elan Pharmaceuticals, Inc. |
Methods and compositions for treating rheumatoid arthritis
|
|
US8795693B2
(en)
|
2003-08-04 |
2014-08-05 |
Foamix Ltd. |
Compositions with modulating agents
|
|
SE0400235D0
(sv)
|
2004-02-06 |
2004-02-06 |
Active Biotech Ab |
New composition containing quinoline compounds
|
|
US8314124B2
(en)
|
2004-02-06 |
2012-11-20 |
Active Biotech Ab |
Crystalline salts of quinoline compounds and methods for preparing them
|
|
JP2007531735A
(ja)
|
2004-04-01 |
2007-11-08 |
エラン ファーマシューティカルズ，インコーポレイテッド |
ステロイド節約剤および該節約剤を使用する方法
|
|
EP1796710A4
(en)
|
2004-09-02 |
2010-05-26 |
Teva Pharma |
THERAPY COMBINED WITH GLATIRAMER ACETATE AND N-ACETYLCYSTEINE TO TREAT MULTIPLE SCLEROSIS
|
|
HRP20160455T1
(hr)
|
2004-09-09 |
2016-07-15 |
Yeda Research And Development Co., Ltd. |
Smjese polipeptida, sastavi koji ih sadrže i postupci za njihovu pripremu, te njihove primjene
|
|
US20060205822A1
(en)
|
2004-12-22 |
2006-09-14 |
Forest Laboratories, Inc. |
1-Aminocyclohexane derivatives for the treatment of multiple sclerosis, emotional lability and pseudobulbar affect
|
|
CA2595159A1
(en)
|
2005-01-13 |
2006-07-20 |
Sirtris Pharmaceuticals, Inc. |
Novel compositions for preventing and treating neurodegenerative and blood coagulation disorders
|
|
WO2006129178A1
(en)
|
2005-06-02 |
2006-12-07 |
Glenmark Pharmaceuticals S.A. |
Novel cannabinoid receptor ligands, pharmaceutical compositions containing them, and process for their preparation
|
|
NZ597082A
(en)
|
2005-10-13 |
2013-11-29 |
Human Genome Sciences Inc |
Methods and Compositions for Use in Treatment of Patients with Autoantibody Positive Diseases
|
|
US9168286B2
(en)
|
2005-10-13 |
2015-10-27 |
Human Genome Sciences, Inc. |
Methods and compositions for use in treatment of patients with autoantibody positive disease
|
|
HRP20141160T1
(hr)
|
2005-10-19 |
2015-01-16 |
Teva Pharmaceutical Industries Ltd. |
Kristali natrijevog lakvinimoda i postupak za njihovu proizvodnju
|
|
KR20080064880A
(ko)
|
2005-10-26 |
2008-07-09 |
라보라뚜와르 세로노 에스. 에이. |
술폰아미드 유도체 및 금속단백분해효소를 조정하기 위한그것의 용도
|
|
US20080108641A1
(en)
|
2006-02-08 |
2008-05-08 |
Ajami Alfred M |
Compounds for treating inflammatory disorders, demyelinating disdorders and cancers
|
|
US8367629B2
(en)
|
2006-02-14 |
2013-02-05 |
Noxxon Pharma Ag |
MCP-1 binding nucleic acids and use thereof
|
|
US8410115B2
(en)
*
|
2006-02-28 |
2013-04-02 |
Elan Pharmaceuticals, Inc. |
Methods of treating inflammatory and autoimmune diseases with alpha-4 inhibitory compounds
|
|
EP4276469A3
(en)
|
2006-02-28 |
2024-01-17 |
Biogen MA Inc. |
Methods of treating inflammatory and autoimmune diseases with natalizumab
|
|
AU2007224228B2
(en)
|
2006-03-03 |
2013-09-19 |
Biogen Ma Inc. |
Methods of treating inflammatory and autoimmune diseases with natalizumab
|
|
WO2007109052A2
(en)
|
2006-03-16 |
2007-09-27 |
Genentech, Inc. |
Methods of treating lupus using cd4 antibodies
|
|
EP2010214A4
(en)
|
2006-04-10 |
2010-06-16 |
Abbott Biotech Ltd |
USES AND COMPOSITIONS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS
|
|
WO2007146331A1
(en)
|
2006-06-12 |
2007-12-21 |
Teva Pharmaceutical Industries, Ltd. |
Tannate salt form of polypeptide mixtures, their preparation and use
|
|
ES2377149T3
(es)
|
2006-06-12 |
2012-03-22 |
Teva Pharmaceutical Industries Limited |
Preparaciones de laquinimod estables
|
|
MX2009000645A
(es)
|
2006-07-17 |
2009-03-06 |
Novartis Ag |
Derivados de sulfonilaminocarbonilo de amidas de acido biliar para utilizarse en la forma de inmunomoduladores.
|
|
EP1886996A1
(en)
|
2006-08-10 |
2008-02-13 |
Ferrer Internacional, S.A. |
1H-Quinolin-4-one compounds, with affinity for the GABA receptor, processes, uses and compositions
|
|
EP2056818B1
(en)
|
2006-08-11 |
2011-05-25 |
The Johns Hopkins University |
Compositions and methods for neuroprotection
|
|
SI2056807T1
(sl)
|
2006-08-17 |
2012-12-31 |
University Of Chicago |
Zdravljenje vnetnih bolezni
|
|
US20100136125A1
(en)
|
2006-12-28 |
2010-06-03 |
Jacobus Pharmaceutical Company, Inc. |
Method of treating inflammatory bowel disease
|
|
PT2187882E
(pt)
|
2007-07-11 |
2013-04-17 |
Medicinova Inc |
Tratamento de uma doença neurodegenerativa progressiva com ibudilast
|
|
WO2009053070A1
(en)
|
2007-10-23 |
2009-04-30 |
Schwarz Pharma Ag |
Compounds for treating demyelination conditions
|
|
SI2234485T1
(sl)
|
2007-12-20 |
2014-03-31 |
Teva Pharmaceutical Industries Ltd. |
Stabilni lakvinimodni pripravki
|
|
ES2329327B1
(es)
|
2008-03-19 |
2010-09-17 |
Proyecto De Biomedicina Cima, S.L. |
Combinaciones sinergicas de 5'-metiltioadenosina.
|
|
KR20110048571A
(ko)
|
2008-09-03 |
2011-05-11 |
테바 파마슈티컬 인더스트리즈 리미티드 |
면역 기능을 지닌 ２―옥소―１,２―다이하이드로―퀴놀린 조절제
|
|
TW201438738A
(zh)
|
2008-09-16 |
2014-10-16 |
建南德克公司 |
治療進展型多發性硬化症之方法
|
|
TWI404721B
(zh)
|
2009-01-26 |
2013-08-11 |
Pfizer |
胺基－雜環化合物
|
|
UY32427A
(es)
|
2009-02-13 |
2010-09-30 |
Boheringer Ingelheim Internat Gmbh |
Composicion farmaceutica, forma farmaceutica, procedimiento para su preparacion, metodos de tratamiento y usos de la misma
|
|
PT2442651E
(pt)
|
2009-06-19 |
2015-10-22 |
Teva Pharma |
Tratamento da esclerose múltipla com laquinimod
|
|
AU2010276748A1
(en)
|
2009-07-30 |
2012-03-15 |
Teva Pharmaceutical Industries Ltd. |
Treatment of Crohn's disease with laquinimod
|
|
HUE029983T2
(en)
|
2009-08-10 |
2017-04-28 |
Teva Pharma |
Treatment of BDNF-related diseases with laquinimod
|
|
DE102010026879A1
(de)
*
|
2010-02-11 |
2011-08-11 |
AMW GmbH, 83627 |
Transdermales System mit Immunmodulator
|
|
KR20130036217A
(ko)
|
2010-03-03 |
2013-04-11 |
테바 파마슈티컬 인더스트리즈 리미티드 |
라퀴니모드를 이용한 루푸스 관절염의 치료
|
|
US8501766B2
(en)
|
2010-03-03 |
2013-08-06 |
Teva Pharmaceutical Industries Ltd. |
Treatment of rheumatoid arthritis with a combination of laquinimod and methotrexate
|
|
KR20130006640A
(ko)
|
2010-03-03 |
2013-01-17 |
테바 파마슈티컬 인더스트리즈 리미티드 |
라퀴니모드를 이용한 루푸스 신장염의 치료
|
|
MX2013000333A
(es)
|
2010-07-09 |
2013-02-26 |
Teva Pharma |
N-etil-n-fenil-1,2-dihidro-4-hidroxi-5-cloro-1-metil-2-oxoquinoli na-3-carboxamida deuterada, sales y usos de la misma.
|
|
WO2012006544A1
(en)
|
2010-07-09 |
2012-01-12 |
Teva Pharmaceutical Industries Ltd. |
5-chloro-4-hydroxy-1-methyl-2-oxo-n-phenyl-1,2-dihydroquinoline-3-carboxamide, salts and uses thereof
|
|
EP2648732A4
(en)
|
2010-12-07 |
2014-04-30 |
Teva Pharma |
USE OF LAQUINIMOD TO REDUCE TEMPERATURE, IMPROVE FUNCTIONAL STATUS AND IMPROVE LIFE QUALITY IN PATIENTS WITH MULTIPLE SCLEROSIS
|
|
ES2602794T3
(es)
|
2011-03-31 |
2017-02-22 |
Pfizer Inc |
Piridinonas bicíclicas novedosas
|
|
US20130028866A1
(en)
|
2011-07-28 |
2013-01-31 |
Yossi Gilgun |
Treatment of multiple sclerosis with combination of laquinimod and interferon-beta
|
|
CN103781354A
(zh)
|
2011-07-28 |
2014-05-07 |
泰华制药工业有限公司 |
用拉喹莫德与醋酸格拉替雷的组合治疗多发性硬化症
|
|
JP2014530821A
(ja)
|
2011-10-12 |
2014-11-20 |
テバ ファーマシューティカル インダストリーズ リミティド |
ラキニモドおよびフィンゴリモドを組み合わせた多発性硬化症の治療
|
|
EP3225617A1
(en)
|
2012-02-16 |
2017-10-04 |
Teva Pharmaceutical Industries Ltd |
N-ethyl-n-phenyl-1,2-dihydro-4,5-di-hydroxy-1-methyl-2-oxo-3-quinoline carboxamide, preparation and uses thereof
|
|
US20130259856A1
(en)
|
2012-03-27 |
2013-10-03 |
Teva Pharmaceutical Industries, Ltd. |
Treatment of multiple sclerosis with combination of laquinimod and dimethyl fumarate
|
|
TW201804997A
(zh)
|
2012-05-02 |
2018-02-16 |
以色列商泰瓦藥品工業有限公司 |
高劑量拉喹莫德(laquinimod)於治療多發性硬化症之用途
|
|
TW201350467A
(zh)
|
2012-05-08 |
2013-12-16 |
Teva Pharma |
Ｎ－乙基－４－羥基－１－甲基－５－（甲基（２，３，４，５，６－五羥基己基）胺基）－２－側氧－ｎ－苯基－１，２－二氫喹啉－３－甲醯胺
|
|
TW201400117A
(zh)
|
2012-06-05 |
2014-01-01 |
Teva Pharma |
使用拉喹莫德治療眼發炎疾病
|
|
US20130345257A1
(en)
|
2012-06-26 |
2013-12-26 |
The Regents Of The University Of California |
Composition for lupus nephritis and methods of making and using the same
|
|
AR091706A1
(es)
|
2012-07-11 |
2015-02-25 |
Teva Pharma |
Formulaciones de laquinimod sin agentes alcalinizantes
|
|
UY34896A
(es)
|
2012-07-12 |
2014-02-28 |
Teva Pharma |
Tratamiento de la esclerosis múltiple con una combinación de laquinimod y fampridina
|
|
TW201410244A
(zh)
|
2012-08-13 |
2014-03-16 |
Teva Pharma |
用於治療ｇａｂａ媒介之疾病之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ）
|
|
TW201410243A
(zh)
|
2012-08-13 |
2014-03-16 |
Teva Pharma |
用於治療大麻素受體型１（ｃｂ１）媒介之疾病之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ）
|
|
JP2015533163A
(ja)
|
2012-10-12 |
2015-11-19 |
テバ ファーマシューティカル インダストリーズ リミティド |
多発性硬化症における視床損傷を低減するためのラキニモド
|
|
EA201590788A1
(ru)
|
2012-11-07 |
2015-12-30 |
Тева Фармасьютикал Индастриз Лтд. |
Аминные соли лахинимода
|
|
HK1218254A1
(zh)
|
2013-02-15 |
2017-02-10 |
Teva Pharmaceutical Industries Ltd. |
用拉喹莫德治疗多发性硬化症
|
|
MX2015010967A
(es)
|
2013-03-14 |
2015-10-26 |
Teva Pharma |
Formulaciones transdermicas de laquinimod.
|
|
HK1220444A1
(zh)
|
2013-03-14 |
2017-05-05 |
Teva Pharmaceutical Industries Ltd. |
拉喹莫德钠晶体和用於制造它们的改进方法
|
|
EP3094330A4
(en)
*
|
2014-01-17 |
2017-09-27 |
Teva Pharmaceutical Industries Ltd |
Treatment of crohn's disease using low doses of laquinimod
|